| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 90999 |
|
29,415 |
2,471 |
$4.23M |
| A4657 |
Syringe, with or without needle, each |
3,442 |
1,308 |
$14K |
| Q4081 |
Injection, epoetin alfa, 100 units (for esrd on dialysis) |
22,042 |
1,613 |
$8K |
| J1756 |
Injection, iron sucrose, 1 mg |
7,720 |
1,876 |
$2K |
| J0887 |
Injection, epoetin beta, 1 microgram, (for esrd on dialysis) |
1,044 |
570 |
$2K |
| 90661 |
|
14 |
14 |
$449.57 |
| 83970 |
|
1,014 |
946 |
$368.88 |
| 90674 |
|
50 |
49 |
$36.74 |
| 0124A |
|
23 |
23 |
$8.36 |
| 85041 |
|
1,237 |
1,088 |
$0.00 |
| 85045 |
|
317 |
297 |
$0.00 |
| 90662 |
|
18 |
18 |
$0.00 |
| 85048 |
|
1,212 |
1,066 |
$0.00 |
| 82108 |
|
143 |
134 |
$0.00 |
| 83540 |
|
639 |
558 |
$0.00 |
| 82728 |
|
652 |
574 |
$0.00 |
| 0250 |
|
11,356 |
656 |
$0.00 |
| G0499 |
Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result |
1,057 |
727 |
$0.00 |
| 83550 |
|
486 |
413 |
$0.00 |
| 82306 |
|
399 |
349 |
$0.00 |
| J1270 |
Injection, doxercalciferol, 1 mcg |
4,044 |
393 |
$0.00 |
| 0064A |
|
12 |
12 |
$0.00 |
| 90747 |
|
28 |
28 |
$0.00 |
| 82746 |
|
17 |
17 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
38 |
38 |
$0.00 |